Table 2:
Depression, Anxiety, and Adherence at Baseline and 10-Weeks
| Measure a | Group Assignment |
P | |
|---|---|---|---|
| Placebo (n = 73) | Omega-3 (n = 71) | ||
| Beck Depression Inventory II (BDI-II) | |||
| Baseline b | 29.1 (8.8) | 29.9 (9.0) | .59 |
| Post Treatment (10 weeks) c | 9.1 (7.7) | 11.0 (9.9) | .20 |
| Hamilton Rating Scale for Depression (HAM-D) | |||
| Baseline b | 17.0 (5.0) | 17.4 (5.4) | .67 |
| Post Treatment c | 6.2 (5.5) | 7.1 (7.0) | .38 |
| Patient Health Questionnaire (PHQ-9) | |||
| Baseline b | 15.4 (4.1) | 15.9 (4.6) | .54 |
| Post Treatment c | 4.9 (4.7) | 5.4 (5.2) | .60 |
| Beck Anxiety Inventory (BAI) | |||
| Baseline b | 12.4 (9.7) | 12.7 (10.0) | .83 |
| Post Treatment c | 6.4 (7.2) | 7.6 (9.0) | .34 |
| Cumulative mean treatment adherence (% days pill removed) | |||
| Omega-3/Placebo | 95.9 (5.8) | 95.3 (5.8) | .53 |
| Sertraline | 97.5 (3.8) | 97.6 (3.2) | .87 |
| Omega-3 % RBC | |||
| EPA | |||
| Baseline a | 0.48 (0.19) | 0.46 (0.18) | .48 |
| Post Treatment b | 0.51 (0.40) | 1.74 (0.77) | <.0001 |
| DHA | |||
| Baseline a | 4.06 (1.05) | 3.83 (0.93) | .18 |
| Post Treatment 10 weeks (n = 124) b | 4.06 (0.89) | 3.86 (1.09) | .23 |
a
Continuous outcomes are reported as mean (SD)
b
All baseline means were imputed due to limited missing data on two participants assigned to the placebo arm.
c
Post treatment means are not adjusted for the baseline score.
Abbreviations: EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; RBC = red blood cells